Radiologische Diagnostik von Gliomen und Hirnmetastasen: State of the Art der Standardverfahren und experimentelle neue Methoden

Bei der radiologischen Diagnostik von Gliomen und Hirnmetastasen spielt die MRT die entscheidende Rolle als Grundlage für die Differenzialdiagnostik und im späteren Verlauf beim Therapiemonitoring. Dieser Beitrag fasst den aktuellen klinischen Stand zusammen und gibt einen Ausblick auf fortgeschrittene Methoden wie die quantifizierbare MRT- und nuklearmedizinische Bildgebung.

• Literatur

• 1 Peters S. Knöß N. Wodarg F. et al. Glioblastomas vs. lymphomas: more diagnostic certainty by using susceptibility-weighted imaging (SWI). Fortschr Röntgenstr 2012; 184: 713-718
• 2 Wen PY. Macdonald DR. Reardon DA. et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 2010; 28: 1963-1972
• 3 Moffat BA. Chenevert TL. Lawrence TS. et al. Functional diffusion map: a noninvasive MRI biomarker for early stratification of clinical brain tumor response. Proc Natl Acad Sci USA 2005; 102: 5524-5529
• 4 Taal W. Brandsma D. de Bruin HG. et al. Incidence of early pseudo-progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide. Cancer 2008; 113: 405-410
• 5 Brandsma D. Stalpers L. Taal W. et al. Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. Lancet Oncol 2008; 9: 453-461
• 6 Boxerman JL. Ellingson BM. Jeyapalan S. et al. Longitudinal DSC-MRI for distinguishing tumor recurrence from pseudoprogression in patients with a high-grade glioma. Am J Clin Oncol 2014; (Epub ahead of print)
• 7 Server A. Orheim TE. Graff BA. et al. Diagnostic examination performance by using microvascular leakage, cerebral blood volume, and blood flow derived from 3-T dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging in the differentiation of glioblastoma multiforme and brain metastasis. Neuroradiology 2011; 53: 319-330
• 8 Liao W. Liu Y. Wang X. et al. Differentiation of primary central nervous system lymphoma and high-grade glioma with dynamic susceptibility contrast-enhanced perfusion magnetic resonance imaging. Acta Radiol 2009; 50: 217-225
• 9 Weber MA. Henze M. Tuttenberg J. et al. Biopsy targeting gliomas: do functional imaging techniques identify similar target areas?. Invest Radiol 2010; 45: 755-768
• 10 Müller A. Jurcoane A. Kebir S. et al. Quantitative T1-mapping detects cloudy-enhancing tumor compartments predicting outcome of patients with glioblastoma. Cancer Med 2017; 6: 89-99
• 11 Esmaeli M. Vettukattil R. Bathen TF. 2-hydroxyglutarate as a magnetic resonance biomarker for glioma subtyping. Transl Oncol 2013; 6: 92-98
• 12 Roessler K. Gatterbauer B. Becherer A. et al. Surgical target selection in cerebral glioma surgery: linking methionine (MET) PET image fusion and neuronavigation. Minim Invasive Neurosurg 2007; 50: 273-280
• 13 Chaumeil MM. Gini B. Yang H. et al. Longitudinal evaluation of MPIO-labeled stem cell biodistribution in glioblastoma using high resolution and contrast-enhanced MR imaging at 14.1 tesla. Neuro Oncol 2012; 14: 1050-1061
• 14 http://www.cancerimagingarchive.net